The role of the European Medicines Agency and its pandemic task force during the COVID-19 crisis
Case SI/5/2020/DDJ - Opened on Wednesday | 29 July 2020
In the context of wider strategic work on the response of the EU administration during the COVID-19 crisis, the Ombudsman has also been examining the work of the European Medicines Agency (EMA). In particular, the Ombudsman has looked at the role of EMA's newly-established pandemic task force (COVID-ETF), which was created to help EU Member States and the European Commission take quick and coordinated regulatory action on the development, authorisation and safety monitoring of medicines intended for the treatment and prevention of COVID-19.
The Ombudsman has asked EMA to provide more information on the role of the COVID-ETF and the transparency and independence of decisions taken in the context of the COVID-19 response.